Pharma Sector Earnings Preview - IPM Growth Led By Covid-19 Driven Products To Taper Off In Q2: Nirmal Bang
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Nirmal Bang Report
In Q2 FY22, growth from Covid-19 driven products in the domestic branded formulation sales should dissipate on a QoQ basis as new Covid cases have declined sharply.
But, higher anti infective sales on account of a seasonally strong quarter should take some pressure off.
U.S. volume growth remains flattish, with a few exceptions.
Dr. Reddy’s Laboratories Ltd.'s U.S. growth may be quite strong as it also is expected to benefit from new launches and ramp up in gCiprodex volumes.
gCiprodex prescription volume in the U.S. market has more than doubled in Q2 FY22.
Cipla Ltd. and Lupin Ltd. have gained meaningful market share in gBrovana and Albuterol Sulphate in the U.S. market.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.